Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASCO 2024

American Society of Clinical Oncology

31 May–04 June 2024 | Chicago, IL

The 2024 ASCO Annual Meeting was held in Chicago, IL, from May 31-June 4, and was a unique opportunity for clinicians and researchers to come together and share the latest innovations in cancer care and research.

View all videos

Advice for physicians when managing bispecific antibody treatment for patients with myeloma

Monique Minnema • 2 Jun 2024

The potential of immunotherapies in the myeloma treatment landscape

Monique Minnema • 2 Jun 2024

Overview of the toxicities associated with bispecific agents in multiple myeloma

Monique Minnema • 2 Jun 2024

BENEFIT trial: isatuximab, lenalidomide, and dexamethasone +/- bortezomib in newly diagnosed myeloma

Xavier Leleu • 31 May 2024

Advice for physicians when managing bispecific antibody treatment for patients with myeloma

Monique Minnema • 2 Jun 2024

The potential of immunotherapies in the myeloma treatment landscape

Monique Minnema • 2 Jun 2024

The current SoC for patients with primary CNS lymphoma

Lakshmi Nayak • 2 Jun 2024

Defining primary refractory disease and its effect on patient outcomes in DLBCL

Allison Marie Bock • 11 Jul 2024

Investigating the impact of frailty on outcomes of patients with AML

Aniket Bankar • 3 Jun 2024

Germline predisposition to clonal hematopoiesis and its role in leukemia progression

Kelly Bolton • 1 Jun 2024

Updates in MPNs from ASCO 2024: combination therapies, trial endpoints & future directions

Lucia Masarova • 2 Jun 2024

SIMPLIFY studies: analysis of the meaningful symptomatic change in patients with myelofibrosis

Ruben Mesa • 2 Jun 2024